FREE Case Review (866) 588-0600

Invokana Lawsuits Consolidated in New Jersey

A panel of judges has ordered that all federal lawsuits alleging ketoacidosis and kidney failure from the diabetes medications Invokana and Invokamet will be transferred to the District of New Jersey.

A panel of judges has ordered that all federal lawsuits alleging ketoacidosis and kidney failure from the diabetes medications Invokana (generic: canagliflozin) and Invokamet (generic: canagliflozin and metformin) will be transferred to the District of New Jersey before Judge Brian R. Martinotti.

Free Confidential Lawsuit Evaluation: If you or a loved one was injured by Invokana side effects, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What’s the problem?

December 19, 2016 – Johnson & Johnson and its subsidiary Janssen Pharmaceuticals currently face about 55 Invokana lawsuits in federal courts across the U.S. The complaints allege that the companies failed to adequately warn about the risk of Invokana side effects, which include diabetic ketoacidosis, kidney failure, heart attack, stroke and more.

Multidistrict litigations are used in complex pharmaceutical litigation in which multiple lawsuits are filed alleging similar injuries. They are intended to reduce duplicative discovery, avoid conflicting rulings by different judges, and to serve the convenience of all parties involved. J&J was in favor of consolidation, according to court documents.

The MDL will only include lawsuits regarding Invokana and Invokamet. Similar claims have been alleged against other diabetes medications from the sodium glucose cotransporter 2 (SALT-2) inhibitor class, which include Farxiga (dapagliflozin), Jardiance (empagliflozin), Glyxambi (empagliflozin and linagliptin) and Xigduo XR (dapagliflozin and metformin hydrochloride extended-release).

JPML determined that the litigation will not include claims stemming from the 4 other drugs because there was a risk of complicating case management in the MDL. The four other drugs are not made by Janssen or J&J.

“Centralizing competing defendants in the same MDL may unnecessarily complicate case management, due to the need to protect trade secret and confidential information,” the transfer order stated. “In addition, a multi-defendant MDL may prolong pretrial proceedings, because of, inter alia, the possible need for separate discovery and motion tracks, as well as the need for additional bellwether trials.”

Janssen has a lot at stake in the upcoming litigation. Invokana generated about $1 billion in sales last year alone. The company is trying to remove a number of complaints filed in Pennsylvania state court, and also using a federal preemption rule to dismiss state lawsuits. However, while Janssen is trying to mitigate as many cases as it can, plaintiffs injured by Invokana side effects aren’t going down without a fight.

Do I Have an Invokana Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Invokana lawsuits. We are handling individual litigation nationwide and currently accepting new diabetic ketoacidosis and kidney failure cases in all 50 states.

Free Case Evaluation: Again, if you were injured by the side effects of Invokana, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
*
*
*
Awards & recognition